Adalank
N-Acetyl Selank Amidate · Enhanced Tuftsin Analog
Derivative of Selank, modified for greater stability, better crossing of the blood-brain barrier, and a longer half-life than the parent compound. Selank itself has been approved in Russia since the early 2000s.
Overview
Derivative of Selank, modified for greater stability, better crossing of the blood-brain barrier, and a longer half-life than the parent compound. Selank itself has been approved in Russia since the early 2000s.
GABAergic neurotransmission is modulated, hippocampal BDNF upregulated, serotonin metabolism influenced, and immunomodulatory effects delivered — none of it accompanied by benzodiazepine-like dependency.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Effects comparable to benzodiazepines in clinical trials, with rapid response in 40% inside 1–3 days.
Stress hormones fall and neurotransmitters balance, with no sedation.
Relief arrives without tolerance, withdrawal, or dependency, which sets it apart from benzodiazepines.
Mental clarity, attention, and focus improve.
Memory formation is supported by BDNF-mediated neuroplasticity.
BDNF expression rises rapidly, and neuronal survival is supported.
Capacity to handle psychological stress is enhanced.
- Class
- Modified heptapeptide
- Research status
- Emerging
- Chain length
- 7 residues
- Molecular weight
- 792.93 Da
- Typical dose
- 200–500 µg
- Frequency
- Once or twice daily
- Cycle length
- 2–4 weeks
- Storage
- Lyophilized: room temp or freezer. Reconstituted: 2-8°C for 14-30 days
Molecular data
- Type
- Modified heptapeptide
- Molecular weight
- 792.93 Da
- Chain length
- 7 residues
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Anxiety Reduction | SubQ | 200-300mcg | 1x daily (morning) |
| Cognitive Enhancement | SubQ | 200-500mcg | 1x daily |
| Stress Management | SubQ | 200-300mcg | 2x daily (morning, afternoon) |
| Initial Trial | SubQ | 100-200mcg | 1x daily |
| Anxiety Management | Nasal spray | 200-300mcg per dose | 2-3x daily (600-900mcg total) |
| Initial Trial | Nasal spray | 150-200mcg per dose | 2x daily |
Interactions
As an enhanced derivative, Adalank gains stability and a longer half-life.
Two Russian nootropic peptides whose mechanisms differ.
Mechanisms differ: neurological pathways for Adalank, tissue repair for BPC-157.
In research studies, benzodiazepine effects are enhanced and side effects reduced.
Neurotransmitter systems are affected; a healthcare provider should be consulted.
What to expect
Safety
Mechanistic flags — properties of the pathway, not observed adverse events.
- Russian clinical research gives the parent compound a high safety profile
- Side effects reported as minimal
- Unusual neurological symptoms
- Severe gastrointestinal distress
- Headaches, unusual or persistent
- Sedation that was not expected, or extreme fatigue
- Injection site reactions that persist, or nasal irritation
- Marked change in mood, or depression
- An experimental peptide; direct human research on the N-Acetyl form is limited
- A healthcare provider should be consulted before use alongside psychiatric medications
- Pregnancy or breastfeeding: not recommended
Quality checklist
What to confirm before trusting a batch of research material. A verification aid — not an endorsement of any supplier.
- Third-party Certificate of AnalysisIndependent lab · dated · lot-matched.
- HPLC purity ≥ 98%Reverse-phase trace included.
- Mass-spec confirms 792.93 g/molMALDI-TOF or ESI-MS.
- Counterion stated (acetate ≫ TFA)TFA salts can confound bioassays.
- Endotoxin / sterility statementRelevant once reconstituted.
- Lyophilised · cold-chain shippedStored −20 °C, shipped on ice.
- Labelled “research use only”No therapeutic or dosing claims.
Recorded signals for this compound · 6
- ✓Fluffy white powder, indicating that freeze-drying was done properly
- ✓Reconstituted solution is clear, showing neither particles nor cloudiness
- ✓Labeling done properly: peptide name, batch number, and date of manufacture
- !Compaction that is slight and shipping-related is acceptable, provided the powder dissolves on a gentle swirl
- ×Cloudiness or particles that persist indicate the peptide is degraded or contaminated
- ×Oxidation or degradation is indicated by discoloration or yellowing
FAQ
Against benzodiazepines, how quickly does Adalank act on anxiety?
Clinical trials recorded rapid anxiety reduction inside 1–3 days in 40% of GAD patients on Adalank — comparable to benzodiazepines such as medazepam. Where benzos differ: relief here comes without tolerance, dependency, or withdrawal after discontinuation.
Is Adalank combined with benzodiazepines or SSRIs?
In rat studies, the benzodiazepine anxiolytic effect was enhanced while sedation and memory impairment side effects fell. Alongside SSRIs, neurotransmitter systems are affected on both sides, so monitoring is recommended. Healthcare providers should be consulted ahead of any combination with psychiatric medications.
How does Adalank differ from regular Selank?
An N-acetyl form carrying C-terminal amidation is what Adalank is. Measured against the parent compound Selank, it gains stability, penetrates the blood-brain barrier better, and holds an extended half-life — more potent and longer-acting, then, on anxiolytic and BDNF-upregulating mechanisms that stay the same.
Is cycling required with Adalank, as with other nootropic peptides?
Yes. Breaks of 1–2 weeks between cycles prevent tolerance from developing. The primary advantage over benzodiazepines is the absence of dependency or withdrawal, but responsiveness is maintained by cycling. A typical protocol runs 2–4 week cycles with 1–2 week breaks after each.